Posted by Michael Wonder on 25 Feb 2022
Assessment of public opinion on transparency at the US Food and Drug Administration
18 February 2022 - Historically, the US FDA has considered much of the oversight of clinical trials, interactions with companies, and review processes to be confidential.
In recent years, however, the agency has faced calls for greater transparency, including in its COVID-19 pandemic response and use of expedited review pathways.
